Comparative modeling and structure based drug repurposing of PAX2 transcription factor for targeting acquired chemoresistance in pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

Comparative modeling and structure based drug repurposing of PAX2 transcription factor for targeting acquired chemoresistance in pancreatic ductal adenocarcinoma

Published:2020-03-25 Issue:6 Volume:39 Page:2071-2078
ISSN:0739-1102
Container-title:Journal of Biomolecular Structure and Dynamics
language:en
Short-container-title:Journal of Biomolecular Structure and Dynamics

Author:

Aier Imlimaong¹,Semwal Rahul²,Raj Utkarsh³,Varadwaj Pritish Kumar¹

Affiliation:

1. Department of Bioinformatics & Applied Sciences, Indian Institute of Information Technology, Allahabad, Uttar Pradesh, India

2. Department of Information Technology, Indian Institute of Information Technology, Allahabad, Uttar Pradesh, India

3. Department of Biotechnology and Bioinformatics, NIIT University, Rajasthan, India

Publisher

Informa UK Limited

Subject

Molecular Biology,General Medicine,Structural Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/07391102.2020.1742793

Reference34 articles.

1. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

2. An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma

3. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer

4. Mycophenolate mofetil and its mechanisms of action

5. A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) Study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ionic liquids inhibit the dynamic transition from α-helices to β-sheets in peptides;Fundamental Research;2024-07

2. In silico approaches for drug repurposing in oncology: a scoping review;Frontiers in Pharmacology;2024-06-11

3. PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-04-04

4. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT/mTOR signaling pathway;The Journal of Pathology;2024-01-07

5. PAX2 Gene Mutation in Pediatric Renal Disorders—A Narrative Review;International Journal of Molecular Sciences;2023-08-13